Document:

EX-10.21

 Exhibit 10.21 
 COMMISSION PROGRAM – SCOTT SCHNEIDER 
 (effective
January 1, 2011) 
  

			
	 Position Title:
	  	Senior Vice President-Corporate and Business Development
	 Description:
	  	Responsible for revenue generation efforts, executive customer relations, strategic growth initiatives and positioning, and market execution.

  

	1.	Commission Structure: 

  

	 	A.	Sales of Software and Hardware: 

 With respect to each contract for the sale of a software license and/or hardware to a new or existing customer of CPSI (whether pursuant to a standard sales contract or a SaaS contract), the commission
rate shall be 0.5% of CPSI’s gross profit or anticipated gross profit, as the case may be, from such sale, calculated as of the date of completion of installation. Commissions are earned at the time of completion of installation of the
applicable software/hardware. The timing of payment of earned commissions shall be in accordance with Section 2 below. 
  

	 	B.	Business Management Services: 

 With respect to each contract entered into for the provision of business management services, the commission rate shall be 1.0% of CPSI’s revenues from such contract during the first two
(2) years following execution of the contract. Commissions are earned at the time that the Company recognizes revenue from such contract under GAAP. The timing of payment of earned commissions shall be in accordance with Section 2 below.

  

	2.	Timing of Commission Payments: 

  

	 	A.	General: Subject to Section 2.B. through Section 2.D. below, commissions earned pursuant to Section 1 above will be paid to the employee on a
monthly basis. 

  

	 	B.	Payment Default By Customer: In the event that a customer defaults on payment for software licenses, hardware or business management services, all commissions
previously paid to the employee on the defaulted customer account shall be deducted from the employee’s future commission payments. In the event that partial payment due from a customer is received, the amount of prior commissions to be
deducted from future commissions will be pro-rata based on the amount of the payment received. For example, if a customer pays only 60% of an invoice, then the employee will retain 60% of the commissions received, with the remaining 40% to be
withheld from future commission payments. 

  

	 	C.	Post-Employment Commission Payments: Except as noted in Section 2.D., below, commissions will not be paid to, or on behalf of, any individual who is no
longer an employee of CPSI, regardless of the reason for the employee’s termination of employment (i.e., whether voluntary, involuntary or otherwise). 

	 	D.	Death: In the event of the death of the employee while employed in good standing with CPSI, the following commissions will be paid to the employee’s
estate/beneficiary(ies) as listed in the employee’s last will and testament (or if no such will, to the employee’s spouse, if any; if not, to the employee’s estate) at the same time that such payments would have been paid to the
employee if the employee had not died: 

  

	 	(i)	Commissions from the installation of software licenses and hardware at new customers during the 90-day period following the employee’s death (to the extent that a
contract for such installation was executed prior to the employee’s death); 

  

	 	(ii)	Commissions from the installation of software licenses and hardware at existing customers during the 90-day period following the employee’s death; and

  

	 	(iii)	Commissions from the provision of business management services during the 90-day period following the employee’s death (to the extent that CPSI has recognized
revenue under GAAP from the provision of such services within such 90-day period). 

  

	3.	Exemption From Section 409A: 

 This Commission Program is intended to be exempt from Section 409A of the Internal Revenue Code of 1986, as amended. 
  

	4.	Modification/Termination: 

 This Commission Program shall remain in full force and effect unless and until modified or terminated by CPSI in its sole discretion. 

  
 2EX-10.22

 Exhibit 10.22 
 COMMISSION PROGRAM – TROY ROSSER 
 (effective January 1,
2011) 
  

			
	 Position Title:
	  	Senior Vice President – Sales
	 Description:
	  	Responsible for overseeing all sales and marketing efforts nationwide.

  

	1.	Commission Structure: 

  

	 	A.	Sales of Software and Hardware – New Customers:1 

 With respect to each contract for the sale of a software license and/or hardware to a new customer of CPSI (whether pursuant to a standard sales contract or a SaaS contract), the commission rate shall be
1.0% of CPSI’s gross profit or anticipated gross profit, as the case may be, from such sale, calculated as of the date of completion of installation. In the event that CPSI’s gross profit from sales of software licenses and hardware to new
customers exceeds $14,000,000 in a calendar year, the commission rate will increase to 1.5% of the gross profit from sales exceeding $14,000,000 in such year. Commissions are earned at the time of completion of installation of the applicable
software/hardware. The timing of payment of earned commissions shall be in accordance with Section 2 below. 
  

	 	B.	Sales of Software and Hardware – Existing Customers: 

 With respect to each contract for the sale of a software license and/or hardware to an existing customer of CPSI (whether pursuant to a standard sales contract or a SaaS contract), the commission rate
shall be 0.5% of CPSI’s gross profit or anticipated gross profit, as the case may be, from such sale, calculated as of the date of completion of installation. Commissions are earned at the time of completion of installation of the applicable
software/hardware. The timing of payment of earned commissions shall be in accordance with Section 2 below. 
  

	 	C.	Business Management Services: 

 With respect to each contract entered into for the provision of business management services, the commission rate shall be 1.0% of CPSI’s revenues from such contract during the first two
(2) years following execution of the contract. Commissions are earned at the time that the Company recognizes revenue from such contract under GAAP. The timing of payment of earned commissions shall be in accordance with Section 2 below.

  

	2.	Timing of Commission Payments: 

  

	 	A.	General: Subject to Section 2.B. through Section 2.D. below, commissions earned pursuant to Section 1 above will be paid to the employee on a
monthly basis. 

  

	 	B.	Payment Default By Customer: In the event that a customer defaults on payment for software licenses, hardware or business management services, all commissions
previously paid to the employee on the defaulted customer account shall be deducted from the employee’s future commission payments. In the event that partial payment due from a customer is received, the amount of prior commissions to be
deducted from future commissions will be pro-rata based on the amount of the payment received. For example, if a customer pays only 60% of an invoice, then the employee will retain 60% of the commissions received, with the remaining 40% to be
withheld from future commission payments. 

  

 

	1 	For purposes of this Commission Program, a customer is considered a “new customer” of CPSI for a period of one year from the date that the first software
module is installed by CPSI with such customer. 

	 	C.	Post-Employment Commission Payments: Except as noted in Section 2.D., below, commissions will not be paid to, or on behalf of, any individual who is no
longer an employee of CPSI, regardless of the reason for the employee’s termination of employment (i.e., whether voluntary, involuntary or otherwise). 

 

	 	D.	Death: In the event of the death of the employee while employed in good standing with CPSI, the following commissions will be paid to the employee’s
estate/beneficiary(ies) as listed in the employee’s last will and testament (or if no such will, to the employee’s spouse, if any; if not, to the employee’s estate) at the same time that such payments would have been paid to the
employee if the employee had not died: 

  

	 	(i)	Commissions from the installation of software licenses and hardware at new customers during the 90-day period following the employee’s death (to the extent that a
contract for such installation was executed prior to the employee’s death); 

  

	 	(ii)	Commissions from the installation of software licenses and hardware at existing customers during the 90-day period following the employee’s death; and

  

	 	(iii)	Commissions from the provision of business management services during the 90-day period following the employee’s death (to the extent that CPSI has recognized
revenue under GAAP from the provision of such services within such 90-day period). 

  

	3.	Exemption From Section 409A: 

 This Commission Program is intended to be exempt from Section 409A of the Internal Revenue Code of 1986, as amended. 
  

	4.	Modification/Termination: 

 This Commission Program shall remain in full force and effect unless and until modified or terminated by CPSI in its sole discretion. 

  
 2Partial Lease Termination Agreement

 Exhibit 10.13.4 

PARTIAL LEASE TERMINATION AGREEMENT 
 This Partial Lease Termination Agreement (this “Agreement”) is entered into as of February 7, 2012, by and between BRITANNIA HACIENDA VIII LLC, a Delaware limited liability company
(“Landlord”), and ALEXZA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). 
 R
E C I T A L S : 
 A. Landlord and Tenant are parties to that certain Lease
(“Office Lease”) dated August 25, 2006, pursuant to which Tenant currently leases approximately 106,894 rentable square feet of space (the “Premises”), consisting of all of the rentable area within the two
(2) buildings located at 2017 Stierlin Court (previously known as 2023 Stierlin Court) (the “2017 Building”) containing approximately 41,290 rentable square feet of space, and 2091 Stierlin Court (the “2091
Building”) containing approximately 65,604 rentable square feet of space, in Mountain View, California (the “Buildings”). The Office Lease, as amended by the First Amendment to Lease dated May 4, 2007, and the Second
Amendment to Lease dated August 28, 2007, is referred to herein as the “Lease”. 
 B. Tenant has sublet
the entire 2017 Building pursuant to two (2) subleases: (i) that certain Sublease dated February 4, 2010 (the “Smith Micro Sublease”), of the entire second floor of the 2017 Building (the “Smith Micro
Space”), to Smith Micro Software, Inc., a Delaware corporation (“Smith Micro”), and (ii) that certain Sublease dated April 21, 2011 (the “Complete Genomics Sublease”), of the entire first floor of
the 2017 Building (the “Complete Genomics Space”), to Complete Genomics, a Delaware corporation (“Complete Genomics”). 
 C. Tenant and Landlord desire to enter into this Agreement in order to terminate the Lease with respect to the 2017 Building, and to release one another from their respective obligations thereunder,
except as otherwise provided herein. 
 A G R E E M E N T :

 NOW, THEREFORE, in consideration of the foregoing recitals and the conditions and the covenants hereinafter contained, and
for other consideration hereinafter set forth, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows. 
 1. Effectiveness of this Lease Termination Agreement. Notwithstanding anything to the contrary contained in this Agreement, this Agreement shall not be effective unless and until
(i) Landlord enters into a new lease with Google Inc., a Delaware corporation, for a portion of the Premises, in a form acceptable to Landlord in its sole and absolute discretion (ii) Tenant and Smith Micro enter into a sublease
termination agreement, in a form acceptable to Tenant in its sole and absolute discretion, and (iii) Tenant and Complete Genomics enter into a sublease termination agreement (the “Sublease Termination Agreement”), in a form
acceptable to Tenant in its sole and absolute discretion. 
 2. Termination of the Lease of 2017 Building.
Landlord and Tenant hereby agree that effective as of March 30, 2012 (the “Termination Date”), Tenant’s lease of the 2017 Building shall terminate. The termination of Tenant’s lease of the 2017 Building shall have no
effect on Tenant’s continuing lease of the 2091 Building, which lease shall continue in full force and effect in accordance with the terms of the Lease (subject to the provisions of Section 3, below). 

3. Termination of Rights. As of the date hereof the following provisions of the Office Lease are deleted and shall be of no
further force or effect: (i) Tenant’s right of first refusal as provided in Section 1.3 of the Office Lease, (ii) Tenant’s right of first offer as provided in Section 1.4 of the Office Lease, and
(iii) Tenant’s option to extend the term as provided in Section 2.6 of the Office Lease. 

  

					
	 688190.04/WLA

183308-00007/2-6-12/ejs/ejs
	 		 	 HCP BRITANNIA SHORELINE
 [Lease Termination Agreement]
 [Alexza Pharmaceuticals]

 4. Surrender of 2017 Building. Tenant hereby agrees to cause Smith Micro to
vacate the Smith Micro Space and surrender and deliver exclusive possession of the Smith Micro Space to Landlord on or before the Termination Date in accordance with the provisions of the Lease, and in “broom clean” condition. Landlord
acknowledges that the Complete Genomics Space will continue to be occupied by Complete Genomics following the Termination Date, and that Tenant has no obligations to restore or remove any items from the Complete Genomics Space (provided that the
foregoing shall not relieve Complete Genomics of its surrender, removal and restoration obligations under the “New Direct Lease” with Landlord, as provided in Section 8, below). Tenant agrees that the terms of the Sublease
Termination Agreement shall require Complete Genomics to remove all furniture, fixtures and equipment from the Complete Genomics Space upon the termination of the New Direct Lease. Following the date hereof, Tenant shall cooperate with Landlord to
ensure surrender of the Smith Micro Space to Landlord, including, without limitation, by working with Landlord's property management team to hand over all utility contracts, providing Landlord with all HVAC and other Building systems repair and
maintenance records, fire and life safety inspection reports, including warranties and vendor information, as-built drawings, and AutoCAD files, to the extent any of the foregoing items are in Tenant’s possession. Tenant shall cause all Smith
Micro signage to be removed, shall remove all personal property and furniture systems from the Smith Micro Space (and repair any damage resulting from such removal), on or before the Termination Date. Tenant shall cause all Building systems and
equipment shall be in good order and repair as of the Termination Date. Tenant’s obligations under this Section 4 shall survive the Termination Date. 
 5. Representations of Tenant. Tenant represents and warrants to Landlord that (a) except as expressly provided in Recital B. above, Tenant has not heretofore assigned or sublet
all or any portion of its interest in the Lease; (b) no other person, firm or entity has any right, title or interest in the Lease; (c) subject to execution and delivery of the sublease termination agreements as set forth in
Section 1, above, Tenant has the full right, legal power and actual authority to enter into this Agreement and to terminate the Lease without the consent of any person, firm or entity; and (d) Tenant has the full right, legal power
and actual authority to bind Tenant to the terms and conditions hereof. Tenant further represents and warrants to Landlord that as of the date hereof there are no, and as of the Termination Date there shall not be any, mechanic’s liens or other
liens encumbering all or any portion of the Premises, by virtue of any act or omission on the part of Tenant, its predecessors, contractors, agents, employees, successors or assigns. Notwithstanding the termination of the Lease and the release of
liability provided for herein, the representations and warranties set forth in this Section 5 shall survive the Termination Date and Tenant shall be liable to Landlord for any inaccuracy or any breach thereof. 

6. Termination of Obligations: Limited Continuing Liability. Notwithstanding the termination of the Lease and the release
of liability provided for herein, Tenant shall remain liable for its indemnification obligations for claims arising prior to the Termination Date (or later date upon which Tenant vacates and surrenders the Premises to Landlord as provided above).
Neither Tenant nor Landlord shall have any obligations with respect to any past, pending or future reconciliation of Operating Expenses after the Termination Date. In the event that Tenant or its subtenant retains possession of the Smith Micro Space
or any part thereof after the Termination Date, then the provisions of Section 2.5 of the Office Lease shall apply. Except as expressly set forth in this Agreement, Tenant is hereby released from Tenant’s obligations with respect to
the 2017 Building as of the Termination Date. 
 7. Attorneys’ Fees. Should any dispute arise between the
parties hereto or their legal representatives, successors and assigns concerning any provision of this Agreement or the rights and duties of any person in relation thereto, the party prevailing in such dispute shall be entitled, in addition to such
other relief that may be granted, to recover reasonable attorneys’ fees and legal costs in connection with such dispute. 

8. Consent to Sublease Terminations and Direct Lease With Complete Genomics; No Restoration Obligations. Landlord will
consent to the termination of the Smith Micro Sublease and the Complete Genomics Sublease, and will enter into a direct lease with Landlord as provided in Section 8 of that certain Consent of Master Landlord to Sublease dated
April 21, 2011, between Landlord, Tenant, and Complete Genomics (the “New Direct Lease”). Landlord hereby confirms that it has inspected the Smith Micro Space and the Complete Genomics Space and hereby confirms that except as
provided in Section 4, above, Tenant shall have no restoration or other obligations with respect to the Complete Genomics Space or Smith 

  

					
	 688190.04/WLA

183308-00007/2-6-12/ejs/ejs
	 	-2-	 	 HCP BRITANNIA SHORELINE
 [Lease Termination Agreement]
 [Alexza Pharmaceuticals]

 
Micro Space. On or before the Termination Date, Tenant shall deliver to Landlord the security deposit currently held by Tenant under the Complete Genomics Sublease, which amount shall be held by
Landlord under the New Direct Lease. 
 9. Governing Law. This Agreement shall be governed and construed under the
laws of the State of California. 
 10. Counterparts. This Agreement may be executed in counterparts, each of
which shall be deemed an original, but such counterparts, when taken together, shall constitute one agreement. 
 11.
Binding Effect. This Agreement shall inure to the benefit of, and shall be binding upon, the parties hereto and their respective legal representatives, successors and assigns. 

12. Time of the Essence. Time is of the essence of this Agreement and the provisions contained herein. 

13. Further Assurances. Landlord and Tenant hereby agree to execute such further documents or instruments as may be
necessary or appropriate to carry out the intention of this Agreement. 
 14. Voluntary Agreement. The parties
have read this Agreement and mutual release as contained herein, and on the advice of counsel they have freely and voluntarily entered into this Agreement. 
 15. Defined Terms. All terms defined in the Lease when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this Agreement.

 IN WITNESS WHEREOF, Landlord and Tenant have executed this Agreement as of the day and year first above written. 

 

											
	“LANDLORD”	 		 	“TENANT”
			
	BRITANNIA HACIENDA VIII LLC,	 		 	ALEXZA PHARMACEUTICALS, INC.,
	a Delaware limited liability company	 		 	a Delaware corporation
					
	By:	 	HCP Estates USA Inc.,	 		 	By:	 	 

		 	a Delaware corporation	 		 		 	
		 		 		 		 	Its:	 	 VP, Finance & Controller

						
		 	By:	 	 

	 		 		 	
		 		 	Jonathan M. Bergschneider	 		 		 	
		 		 	Executive Vice President	 		 		 	

  

					
	 688190.04/WLA

183308-00007/2-6-12/ejs/ejs
	 	-3-	 	 HCP BRITANNIA SHORELINE
 [Lease Termination Agreement]
 [Alexza Pharmaceuticals]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]